)
)
)
VoxCell empowers scientists and drug developers to study drug behavior with unprecedented physiological relevance. Complex tissue models for preclinical screening, from efficacy to vascular toxicity. Elevate your preclinical pipeline by using human-relevant tissues that match your requirements to ensure optimal performance for drug screening. VoxCell tissues allow long term and multi-dose studies (80%+ for up to 21 days). Better understand Drug Efficacy & Safety , Drug Combination Tests, Vascular Toxicity and Permeability, Therapeutic Index Determination, and Morphological and Structural Analysis. With vascular complexity at the core of our innovation, VoxCell delivers human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. Committed to innovation and excellence, VoxCell continues to expand its impact on a global scale. Join us at the forefront of a global shift to reduce animal models in drug development.
Year Founded
2020
Next catalyst (value inflection) update
VoxCell's next catalyst/value inflection will be receiving third party comparative data from our trusted partners to quantify the value of our tissue models regarding predictive power and benefit to the customer (time and money). This will change the conversations regarding BD and increase the value of the company for our shareholders, enabling a strong Series A fundraise.
Expected time of next catalyst update
Mar-26
City
Victoria
Country
Canada
Company CEO or top company official
Karolina Valente, Ph.D - CEO & CSO
Development Phase of Primary Product
Other/Not Applicable
Lead Product in Development
VoxCell Vascularized 3D Tissue Models for preclinical drug development. Our Triple Negative Breast Cancer model is the most developed and in use with clients, followed by Non-Small Cell Lung Cancer, Prostate Cancer, and Barrier Models.
Therapeutic Area
Oncology
Website
https://voxcell.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
